extended-release capsule (Adderall XR)

GPTKB entity

Predicate	Object
gptkbp:instanceOf	gptkb:pharmaceutical_drug_formulation
gptkbp:activeIngredient	gptkb:amphetamine gptkb:dextroamphetamine
gptkbp:approvedBy	gptkb:FDA 2001
gptkbp:brand	Adderall XR
gptkbp:broadcastOn	gptkb:Schedule_II_controlled_substance
gptkbp:contains	mixed amphetamine salts
gptkbp:contraindication	gptkb:glaucoma hyperthyroidism history of drug abuse advanced arteriosclerosis known hypersensitivity to amphetamines moderate to severe hypertension symptomatic cardiovascular disease
gptkbp:duration	approximately 12 hours
gptkbp:form	10 mg 20 mg 5 mg 25 mg 15 mg 30 mg extended-release capsule
gptkbp:genericAvailable	yes
gptkbp:halfLife	10-13 hours
gptkbp:legalStatus	prescription only
gptkbp:manufacturer	gptkb:Shire_Pharmaceuticals
gptkbp:marketedIn	gptkb:Canada gptkb:United_States
gptkbp:mechanismOfAction	gptkb:stimulant
gptkbp:pregnancyCategory	C (US)
gptkbp:prescribes	adolescents adults children
gptkbp:riskFactor	abuse dependence cardiovascular events growth suppression in children
gptkbp:routeOfAdministration	oral
gptkbp:sideEffect	anxiety headache loss of appetite increased heart rate insomnia dry mouth
gptkbp:usedFor	gptkb:attention_deficit_hyperactivity_disorder narcolepsy
gptkbp:bfsParent	gptkb:Adderall
gptkbp:bfsLayer	7
https://www.w3.org/2000/01/rdf-schema#label	extended-release capsule (Adderall XR)